Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Prostate Cancer

Free Subscription Articles published in Am J Clin Oncol Retrieve available abstracts of 24 articles: HTML format Text format

Single Articles

April 2018
1. SATKUNASIVAM R, Lo M, Stern M, Gill IS, et al
   The Role of Provider Characteristics in the Selection of Surgery or Radiation for Localized Prostate Cancer and Association With Quality of Care Indicators.
   Am J Clin Oncol. 2018 Apr 17. doi: 10.1097/COC.0000000000000442.
   PubMed     Text format     Abstract available
   
   
   March 2018
2. J BLEDSOE T, S Park H, E Rutter C, Aneja S, et al
   Impact of Health Insurance Status on Prostate Cancer Treatment Modality Selection in the United States.
   Am J Clin Oncol. 2018 Mar 7. doi: 10.1097/COC.0000000000000423.
   PubMed     Text format     Abstract available
   
   
   January 2018
3. TRAN S, Jorcano S, Falco T, Lamanna G, et al
   Oligorecurrent Nodal Prostate Cancer: Long-term Results of an Elective Nodal Irradiation Approach.
   Am J Clin Oncol. 2018 Jan 8. doi: 10.1097/COC.0000000000000419.
   PubMed     Text format     Abstract available
   
   
   
4. KANG JJ, Reiter RE, Kummer N, DeKernion J, et al
   Wrong to be Right: Margin Laterality is an Independent Predictor of Biochemical Failure After Radical Prostatectomy.
   Am J Clin Oncol. 2018;41:1-5.
   PubMed     Text format     Abstract available
   
   
   December 2017
5. YING J, Wang CJ, Yan J, Liauw SL, et al
   Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy.
   Am J Clin Oncol. 2017;40:612-620.
   PubMed     Text format     Abstract available
   
   
   
6. LAWRENCE YR, Samueli B, Levitin R, Pail O, et al
   Do Prostate Cancer Patients With Markedly Elevated PSA Benefit From Radiation Therapy?: A Population-based Study.
   Am J Clin Oncol. 2017;40:605-611.
   PubMed     Text format     Abstract available
   
   
   May 2017
7. SHAVERDIAN N, Kishan AU, Veruttipong D, Demanes DJ, et al
   Impact of the Primary Information Source Used for Decision Making on Treatment Perceptions and Regret in Prostate Cancer.
   Am J Clin Oncol. 2017 May 23. doi: 10.1097/COC.0000000000000387.
   PubMed     Text format     Abstract available
   
   
   March 2017
8. KISHAN AU, Duchesne G, Wang PC, Rwigema JM, et al
   Discord Among Radiation Oncologists and Urologists in the Postoperative Management of High-Risk Prostate Cancer.
   Am J Clin Oncol. 2017 Mar 15. doi: 10.1097/COC.0000000000000381.
   PubMed     Text format     Abstract available
   
   
   February 2017
9. SHAIKH MP, Alite F, Wu MJ, Solanki AA, et al
   Adjuvant Radiotherapy Versus Wait-and-See Strategy for Pathologic T3 or Margin-Positive Prostate Cancer: A Meta-Analysis.
   Am J Clin Oncol. 2017 Feb 20. doi: 10.1097/COC.0000000000000358.
   PubMed     Text format     Abstract available
   
   
   January 2017
10. MCLAUGHLIN PW, Liss AL, Nguyen PL, Assimos DG, et al
    ACR Appropriateness Criteria Locally Advanced, High-Risk Prostate Cancer.
    Am J Clin Oncol. 2017 Jan 4. doi: 10.1097/COC.0000000000000354.
    PubMed     Text format     Abstract available
    
    
    November 2016
11. BITTNER N, Merrick G, Taira A, Bennett A, et al
    Location and Grade of Prostate Cancer Diagnosed by Transperineal Template-guided Mapping Biopsy After Negative Transrectal Ultrasound-guided Biopsy.
    Am J Clin Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    September 2016
12. HOFFMAN KE, Skinner H, Pugh TJ, Voong KR, et al
    Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial.
    Am J Clin Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    August 2016
13. KISHAN AU, Duchesne G, Wang PC, Rwigema JM, et al
    Does Specialty Bias Trump Evidence in the Management of High-risk Prostate Cancer?
    Am J Clin Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    June 2016
14. HEGDE JV, Collins SP, Fuller DB, King CR, et al
    A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy.
    Am J Clin Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    
15. SHAH C, Kotecha R, Stephans K, Tendulkar R, et al
    Radiation Therapy in Prostate Cancer: Defining the Benefit of Hypofractionation.
    Am J Clin Oncol. 2016.
    PubMed     Text format    
    
    
    
16. ZAORSKY NG, Egleston BL, Horwitz EM, Dicker AP, et al
    The Missing Pieces in Reporting of Randomized Controlled Trials of External Beam Radiation Therapy Dose Escalation for Prostate Cancer.
    Am J Clin Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    April 2016
17. SHILKRUT M, McLaughlin PW, Merrick GS, Vainshtein JM, et al
    Treatment Outcomes in Very High-risk Prostate Cancer Treated by Dose-escalated and Combined-Modality Radiation Therapy.
    Am J Clin Oncol. 2016;39:181-8.
    PubMed     Text format     Abstract available
    
    
    
18. VAINSHTEIN JM, Schipper M, Vance S, Feng FY, et al
    Limitations of the Cancer of the Prostate Risk Assessment (CAPRA) Prognostic Tool for Prediction of Metastases and Prostate Cancer-specific Mortality in Patients Treated With External Beam Radiation Therapy.
    Am J Clin Oncol. 2016;39:173-80.
    PubMed     Text format     Abstract available
    
    
    
19. CREHANGE G, Izaguirre A, Weinberg V, Hsu CC, et al
    Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery.
    Am J Clin Oncol. 2016;39:167-72.
    PubMed     Text format     Abstract available
    
    
    March 2016
20. ZAORSKY NG, Keith SW, Shaikh T, Nguyen PL, et al
    Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities.
    Am J Clin Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    
21. KENDAL WS
    Age Bias in Time From Diagnosis Comparisons of Prostate Cancer Treatment.
    Am J Clin Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    February 2016
22. COLLOCA G, Venturino A, Guarneri D
    Tumor Growth Kinetics Before and After First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: A Prostate-specific Antigen-based Retrospective Analysis.
    Am J Clin Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    December 2015
23. MORAES FY, Leite ET, Hamstra DA, Feng FY, et al
    Self-reported Conflicts of Interest and Trial Sponsorship of Clinical Trials in Prostate Cancer Involving Radiotherapy.
    Am J Clin Oncol. 2015.
    PubMed     Text format     Abstract available
    
    
    
24. WHITE EC, Murphy JD, Chang DT, Koong AC, et al
    Low Toxicity in Inflammatory Bowel Disease Patients Treated With Abdominal and Pelvic Radiation Therapy.
    Am J Clin Oncol. 2015;38:564-9.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: